SUMMARY A placebo controlled, double blind study of aminohydroxypropylidene bisphosphonate (APD), given by monthly intravenous infusion, was conducted in 40 patients with rheumatoid arthritis. Biochemical markers of increased bone resorption, such as fasting urinary calcium/ creatinine ratio and hydroxyproline/creatinine ratio, were suppressed significantly in the APD group to approximately 50% and 60% of the pretreatment level respectively, and serum calcium fell transiently after the first APD infusion. There was no significant effect on disease activity in either the APD or placebo groups as judged by clinical (grip strength, morning stiffness, visual analogue score) or laboratory (haemoglobin, platelet count, erythrocyte sedimentation rate, C reactive protein) criteria. An exception was the articular index which improved to a similar degree in both groups, falling from (mean (SEM)) 13X8 (1X8) to 7-2 (2-2) in the APD group and from 13-7 (1-9) to 6-8 (1.5) in the placebo group. Radiological progression occurred to a similar degree in both groups as assessed by the Sharp index (mean (SEM) 86 (13-1) v 95 (12-9)-APD group; 103 (15-1) v 110 (15-8)-placebo group), but there was no significant change in the Larsen index in either group (mean (SEM) 53 (4-2) v 57 (3.8)-APD; 62 (5-8) v 63 (5-6)-placebo). The lack of effect on radiological progression in the APD group indicates that focal erosive disease may either have progressed as the result of a non-osteoclast related mechanism, or that the intensity of bone resorption was too great to be inhibited by the doses of APD used. The biochemical response to APD presumably reflected inhibition of bone resorption at other sites, suggesting that further studies of the effects of bisphosphates on periarticular and systemic osteoporosis in rheumatoid arthritis may be of interest. 
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Biochemical and haematological measurements were made on blood and second voided 'spot' urine samples obtained after an overnight fast at each clinic attendance using standard automated techniques. Urinary calcium and hydroxyproline excretion were expressed as molar ratios relative to urinary creatinine. Serum calcium was adjusted for albumin as previously described.10 Erythrocyte sedimentation rate was determined by the Westergren method.
Clinical assessment was carried out by the same observer (SHR) in each patient monthly for the first three months, at six months, and again at 12 months. The following measures of disease activity in rheumatoid arthritis'1 were recorded: grip strength (dominant hand; mean of three readings), Ritchie articular index, and early morning stiffness. The patients' subjective assessment of joint pain and stiffness was recorded on a visual analogue scale (from O=no joint pain or stiffness whatsoever to 10=joint pain and stiffness as bad as they could be). At each clinic visit patients were specifically asked about any adverse effects experienced since the previous visit. Radiological progression of joint disease was assessed on paired radiographs obtained immediately before starting treatment and again after 12 months. These were assessed by a radiolog- (mean (SEM)) (1-8) to 7-2 (2-2) in the APD group and from 13-7 (1.9) to 6-8 (1-5) in the placebo group (both significant; p<O-OO1).
In the APD group there was a transient fall in serum calcium one week after the initial infusion, though by one month calcium values had returned to the pretreatment concentration and remained stable thereafter throughout the study period. Serum calcium did not change significantly in the placebo group (Fig. 1) .
Urinary calcium/creatinine fell significantly in the APD group from day 7 and remained suppressed throughout the study period. There were no significant changes in calcium/creatinine values in the placebo group (Fig. 2) .
Urinary hydroxyproline/creatinine values also fell in the APD group, the change being statistically significant from one month onward. There was no change in hydroxyproline/creatinine values in the placebo group (Fig. 3) .
The degree of radiological joint damage, as assessed by the methods of Larsen et at12 and Sharp et al'3 was similar in both treatment groups at the beginning of the study. After 12 months radiological progression was noted in both groups using the Sharp method, whereas there was no significant change in the Larsen scores (Table 2) .
No side effects directly attributable to the APD were observed during the study, though progression of pre-existing pulmonary fibrosis was noted at six months in one patient treated with APD. This patient was an elderly man of 73, who withdrew from the study after two APD doses because of lack of benefit and the inconvenience of having to attend for monthly intravenous infusions. At the time of withdrawal there was no clinical suspicion of progressive pulmonary disease. Transient flu like symptoms were observed in two patients treated with APD after the first infusion, but similar symptoms also occurred in three patients treated with placebo. *p<0-01 from before treatment; **p<0-02 from before treatment.
tAPD=aminohydroxypropylidene bisphosphonate.
In the placebo group 19 pairs of radiographs were available for assessment before and after the study. In the APD group the three patients who dropped out before six months were excluded from analysis, but x rays were analysed from one patient who dropped out after eight months of APD, giving a total of 17 paired radiographs analysed. -
Discussion
In the present study a single 30 mg infusion of APD had a prolonged inhibitory effect on bone resorption as shown by the significant reduction in both calcium/ creatinine and hydroxyproline/creatinine ratios for up to 30 days. These findings concur with previous data in other clinical situations.5-9 Although the fall in hydroxyproline/creatinine ratio was less consistent than that of the calcium/creatinine ratio, this was probably owing to hydroxyproline release from sources other than bone. '4 Despite the above biochemical response hand radiographs before and after 12 months showed no significant effect of APD progression of periarticular bone erosions. It is possible that the focal bone resorption associated with these lesions may either have been non-osteoclast mediated,'5 and therefore resistant to the effects of APD, or have been too intense to be modified by the doses of APD used in the present study. In either event this focal bone resorption presumably contributed little to the sum total of bone resorptive activity going on throughout the skeleton. Thus the biochemical response probably reflected inhibition of bone resorption associated with more diffuse periarticular osteoporosis'6 or even generalised osteoporosis, which appears to be more prevalent in rheumatoid arthritis. ' 
